These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38509334)

  • 1. A new standard of care for advanced-stage urothelial carcinoma.
    Sidaway P
    Nat Rev Clin Oncol; 2024 May; 21(5):336. PubMed ID: 38509334
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Ishihara H; Takagi T
    Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Kondo T
    Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
    [No Abstract]   [Full Text] [Related]  

  • 4. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
    Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
    Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
    [No Abstract]   [Full Text] [Related]  

  • 5. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
    Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
    Apolo AB; Bellmunt J; Cordes L; Gupta S; Powles T; Rosenberg JE; Van Der Heijden MS
    ESMO Open; 2024 Sep; 9(9):103725. PubMed ID: 39236601
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic experience of advanced urothelial tract tumors.
    Nakada T; Akiya T; Yoshikawa M; Umeda K; Katayama T
    Hinyokika Kiyo; 1985 Apr; 31(4):601-6. PubMed ID: 4041118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.
    Hara T; Suzuki K; Okada K; Chiba K; Teishima J; Miyake H
    Int J Urol; 2024 Oct; 31(10):1168-1170. PubMed ID: 38948961
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current developments in urothelial carcinoma].
    Niegisch G; Kramer M
    Urologie; 2024 Oct; 63(10):975-976. PubMed ID: 39373754
    [No Abstract]   [Full Text] [Related]  

  • 11. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
    Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
    Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
    [No Abstract]   [Full Text] [Related]  

  • 12. Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.
    Strusi A; Pinterpe G; Ciccarese C; Pedone RR; Sarcina M; Sardaro V; Belletto R; Totaro A; Racioppi M; Berardi R; Tortora G; Iacovelli R
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):661-664. PubMed ID: 38932631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic chemotherapy of urothelial cancer].
    Wolff JM; Jakse G
    Urologe A; 1992 May; 31(3):W19-24. PubMed ID: 1615589
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic strategies for upper tract urothelial carcinoma.
    Freifeld Y; Krabbe LM; Clinton TN; Woldu SL; Margulis V
    Expert Rev Anticancer Ther; 2018 Aug; 18(8):765-774. PubMed ID: 29848133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    Benjamin DJ; Lythgoe MP; Rezazadeh A
    BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
    Drake MJ; Birder LA
    Eur Urol; 2024 Aug; 86(2):183-184. PubMed ID: 38538426
    [No Abstract]   [Full Text] [Related]  

  • 17. [Not Available].
    Aktuelle Urol; 2024 Aug; 55(4):297-298. PubMed ID: 39047749
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].
    Schmid SC; Gschwend JE; Retz M;
    Aktuelle Urol; 2014 Jan; 45(1):55-63; quiz 64-5. PubMed ID: 24500963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
    Song YS; Cho JS; Cho KS; Doo SH; Chung BH; Kim SJ; Yang WJ; Song KH; Kim CI; Hong SJ
    Urol Int; 2010; 85(1):47-51. PubMed ID: 20234122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimizing treatment of advanced urologic malignancies].
    Heidenreich A; Ohlmann CH; Ozgür E; Pfister D; Sahi D; Thüer D; Engelmann UH
    Urologe A; 2007 Sep; 46(9):1278-84. PubMed ID: 17628781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.